Evidence map›Paper›PMID 36148853›Full record

SynthesisLupus2022

Use of gonadotropin-releasing hormone agonists for ovarian preservation in patients receiving cyclophosphamide for systemic lupus erythematosus: A meta-analysis.

Komal Ejaz, Dania Abid, Paul Juneau, Jun Chu, Sarfaraz Hasni

Open access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Lupus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Komal Ejaz266472The Wright Center for Graduate Medical Education, Scranton, PA, USA.ORCID 0000-0001-9920-289X
Dania Abid518097Idaho College of Osteopathic Medicine, Meridian, ID, USA.
Paul Juneau2511National Institutes of Health Library, Bethesda, MD, USA.
Jun ChuLupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2511National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-4698-387X
Sarfaraz HasniLupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2511National Institutes of Health, Bethesda, MD, USA.
National Institutes of Health · USThe Wright Center for Graduate Medical Education · US

Funding

Intramural NIH HHS Z99 AR999999
6 · The paper itself

Abstract

backgroundCyclophosphamide (CYC) has known cytotoxic effects on ovarian reserve and has been linked to premature ovarian failure (POF) in systemic lupus erythematosus (SLE). The concurrent use of gonadotropin-releasing hormone agonists (GnRHas) is postulated to preserve ovarian function by reducing the number of follicles exposed to CYC, but there is paucity of data to establish its efficacy. We conducted a meta-analysis to summarize the effect of concurrent GnRHa use in persevering ovarian function and pregnancy.

methodsEnglish language databases of PubMed, Embase, and Cochrane were searched to include studies published between 2000 and 2021. Studies in females with rheumatic diseases receiving concurrent GnRHa and CYC therapy to evaluate ovarian preservation as defined by amenorrhea, follicle stimulating hormone (FSH), anti-mullerian hormone (AMH), or estradiol levels or successful pregnancy were included. We used a fixed effect, exact, Mantel-Haenszel approach to estimate the overall odds ratio (OR) and associated 95% confidence intervals (95% CIs).

resultsSeven studies with 218 female patients were included. The ovarian function was preserved in 125/132 (94.6%) of women who received GnRHa concurrently with CYC compared to 50/86 (58%) of women who did not receive GnRHa (OR = 10.3, CI = 4.83-36.29). The OR for pregnancy with GnRHa use = 2.94 (CI = 1.04-9.89).

conclusionOur results based on limited published studies suggest that concurrent GnRHa use preserves ovarian function and increase odds of pregnancy. It can be considered for premenopausal SLE females receiving CYC

Indexed as

Lupus Erythematosus, SystemicPrimary Ovarian InsufficiencyCyclophosphamideFemaleGonadotropin-Releasing HormoneHumansPregnancyCyclophosphamideGonadotropin-Releasing Hormoneand premature ovarian failureautoimmune rheumatic diseasescyclophosphamide side effects

Identifiers

PMID36148853
PMCPMC9811938
OpenAlexW4296806515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.